Stéphane de Botton

19.9k total citations · 1 hit paper
201 papers, 6.2k citations indexed

About

Stéphane de Botton is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Stéphane de Botton has authored 201 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Hematology, 74 papers in Molecular Biology and 62 papers in Genetics. Recurrent topics in Stéphane de Botton's work include Acute Myeloid Leukemia Research (149 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers) and Chronic Myeloid Leukemia Treatments (41 papers). Stéphane de Botton is often cited by papers focused on Acute Myeloid Leukemia Research (149 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers) and Chronic Myeloid Leukemia Treatments (41 papers). Stéphane de Botton collaborates with scholars based in France, United States and Spain. Stéphane de Botton's co-authors include Pierre Fenaux, Xavier Thomas, Hervé Dombret, Emmanuel Raffoux, Claude Preudhomme, Eytan M. Stein, Guido Kroemer, Sylvie Castaigné, Nicolas Boissel and Amir T. Fathi and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Stéphane de Botton

188 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Pau Montesinos, Christian Récher et al. profile →

Peers

Countries citing papers authored by Stéphane de Botton

Since Specialization

Citations

This map shows the geographic impact of Stéphane de Botton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane de Botton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane de Botton more than expected).

Fields of papers citing papers by Stéphane de Botton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane de Botton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane de Botton. The network helps show where Stéphane de Botton may publish in the future.

Co-authorship network of co-authors of Stéphane de Botton

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane de Botton. A scholar is included among the top collaborators of Stéphane de Botton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane de Botton. Stéphane de Botton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CAR T cell–mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis 2025 ·Science Translational Medicine ·(unknown), (unknown), (unknown), (unknown), Véronique Vergé, Arnaud Pagès, (unknown), (unknown), (unknown), (unknown), Vincent Ribrag, (unknown), (unknown), Stéphane de Botton, Laurie Menger, Iléana Antony‐Debré, (unknown), Christophe Marzac, Cristina Castilla Llorente, Camille Bigenwald	0
2	Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial 2025 ·Journal of Hematology & Oncology ·Jörge E. Cortes, Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice S. Mims, Hua Tian, (unknown), Stéphane de Botton, Pau Montesinos, Antonio Curti, Justin M. Watts, (unknown)	7
3	Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm 2024 ·Blood Advances ·(unknown), Arnaud Pagès, (unknown), (unknown), Rudy Birsen, (unknown), Adrien Contejean, Alina Danu, Stéphane de Botton, (unknown), Pierre‐Yves Dumas, Arnaud Jaccard, Anne Marfaing‐Koka, Christophe Willekens, Éric Deconinck, David Ghez	2
4	A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study. 2024 ·Journal of Clinical Oncology ·Maria Teresa Voso, Stéphane de Botton, Michael Pfeilstöcker, (unknown), Kefeng Wang, Wendy L. See, (unknown), Daniel L. Menezes, (unknown), Thomas Prébet, Gail J. Roboz	1
5	Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia. 2024 ·Journal of Clinical Oncology ·Stéphane de Botton, Brian A. Jonas, P. Brent Ferrell, (unknown), Alice S. Mims	1
6	Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials 2024 ·Blood Advances ·Pau Montesinos, Amir T. Fathi, Stéphane de Botton, Eytan M. Stein, Amer M. Zeidan, Yue Zhu, Thomas Prébet, Carlos E. Vigil, (unknown), Xin Yu, Courtney D. DiNardo	7
7	Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome 2024 ·Blood Advances ·Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts, Yazan F. Madanat, Gabrielle T. Prince, (unknown), Stéphane de Botton, Anthony S. Stein, James M. Foran, Martha Arellano, David A. Sallman, Mohammad Sharif Hossain, Dylan M. Marchione, Xiaofei Bai, Prapti A. Patel, Stephanie M. Kapsalis, Guillermo Garcia‐Manero, Amir T. Fathi	21
8	Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML 2023 ·Blood ·(unknown), Nicolas Duployez, (unknown), Juliette Lambert, Maël Heiblig, Mathilde Hunault, Claude Gardin, Stéphane de Botton, Élise Fournier, Cécile Pautas, Christine Terré, Éric Delabesse, Norbert Ifrah, Arnaud Pigneux, (unknown), Christian Récher, Claude Preudhomme, Hervé Dombret, Raphaël Itzykson	0
9	Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study 2023 ·American Journal of Hematology ·Courtney D. DiNardo, Stéphane de Botton, Daniel A. Pollyea, Richard M. Stone, Jessica K. Altman, Amir T. Fathi, Tharin Limsakun, (unknown), Sung Choe, Mohammad Sharif Hossain, Adriana E. Tron, (unknown), Stephanie M. Kapsalis, Shuchi S. Pandya, Eytan M. Stein	5
10	CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia 2023 ·Journal of Clinical Medicine ·Khalil Saleh, Florence Pasquier, Camille Bigenwald, Stéphane de Botton, Vincent Ribrag, Cristina Castilla‐Llorente	7
11	Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation 2023 ·Nature Medicine ·Birgit Geoerger, Manuel Schiff, Virginie Penard‐Lacronique, Niklas Darín, (unknown), (unknown), Antonin Lamazière, (unknown), Clément Pontoizeau, Pablo Berlanga, Stéphane Ducassou, Katharine Yen, Michael Su, David P. Schenkein, Chris Ottolenghi, Stéphane de Botton	5
12	P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME 2023 ·HemaSphere ·Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts, Yazan F. Madanat, Gabrielle T. Prince, (unknown), Stéphane de Botton, Anthony S. Stein, James M. Foran, Martha Arellano, David A. Sallman, Dylan M. Marchione, Xiaofei Bai, Prapti A. Patel, Stephanie M. Kapsalis, Guillermo Garcia‐Manero, Amir T. Fathi	3
13	CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia 2022 ·Nature Communications ·Awatef Allouch, Laurent Voisin, Yanyan Zhang, Syed Qasim Raza, Yann Lécluse, Julien Calvo, Dorothée Selimoglu‐Buet, Stéphane de Botton, Fawzia Louache, Françoise Pflumio, Éric Solary, Jean‐Luc Perfettini	10
14	Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia 2019 ·Blood ·Sung Choe, Hongfang Wang, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Richard M. Stone, Lynn Quek, Zenon Konteatis, Lenny Dang, Vickie Zhang, Hua Liu, Eyal C. Attar, Bin Wu	4
15	Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study 2019 ·Cancers ·Thomas Boyer, (unknown), Adeline Barthélémy, Alice Marceau‐Renaut, Pauline Peyrouze, Soizic Guihard, Pascale Lepelley, Adriana Pleșa, Olivier Nibourel, (unknown), Marc Wetterwald, Nicolas Pottier, Isabelle Plantier, Stéphane de Botton, Hervé Dombret, Céline Berthon, Claude Preudhomme, Christophe Roumier, Meyling Cheok	29
16	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response 2017 ·Blood ·Michael Amatangelo, Lynn Quek, Alan H. Shih, Eytan M. Stein, Mikhail Roshal, Muriel D. David, Benoît Marteyn, Noushin Farnoud, Stéphane de Botton, Olivier Bernard, Bin Wu, Katharine Yen, Martin S. Tallman, Elli Papaemmanuil, Virginie Penard‐Lacronique, Anjan Thakurta, Paresh Vyas, Ross L. Levine	249
17	Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production 2017 ·Blood ·Christophe Willekens, Véronique Saada, Sophie Broutin, (unknown), Aline Renneville, (unknown), Christophe Marzac, Jean‐Baptiste Micol, Éric Solary, Florence Pasquier, Julien Lazarovici, Vincent Ribrag, Claude Preudhomme, Cyril Quivoron, Virginie Penard‐Lacronique, Angélo Paci, Stéphane de Botton	1
18	Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML 2017 ·Blood ·Richard M. Stone, Sung Choe, Vickie Zhang, Benoît Marteyn, Virginie Penard‐Lacronique, Hongfang Wang, Courtney D. DiNardo, Eytan M. Stein, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Eyal C. Attar, Bin Wu, Stéphane de Botton	1
19	High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group 2006 ·Leukemia ·A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux, Thierry de Revel, Xavier Thomas, Nathalie Contentin, Réda Bouabdallah, Cécile Pautas, Pascal Turlure, Oumédaly Reman, Claude Gardin, Bruno Varet, Stéphane de Botton, (unknown), H. Farhat, Sylvie Chevret, Hervé Dombret, Sylvie Castaigné	226
20	Leucémies aiguës lymphoblastiques 2004 ·Hématologie ·Stéphane de Botton	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact